FibroBiologics appoints Jason D. Davis, CPA, as CFO; base salary $350k

FibroBiologics, Inc.

Jason D. Davis appointed CFO effective June 9, 2025; previously CFO at Virax Biolabs, led IPO in July 2022.
Employment agreement includes base salary of $350k, annual bonus up to 40% of base, and sign-on cash bonus of $15k.
Received option grant of 450,000 shares under 2022 Stock Plan; vests 1/4 on first anniversary, then monthly.
Davis has 20+ years finance experience; at HyperDynamics increased market cap from $20M to $700M and raised $200M+.
Appointment comes as FibroBiologics advances toward Phase 1/2 clinical trial for diabetic foot ulcers in H2 2025.

item 5.02item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Jason D. Davis

Chief Financial Officer

FBLG · FibroBiologics, Inc.

Effective: 2025-06-09
Filed: Jun 09, 2025 23:59 UTC

On June 9, 2025, FibroBiologics, Inc. (the “Company”) announced that Jason D. Davis has been appointed as the Company’s Chief Financial Officer, effective as of June 9, 2025 (the “Effective Date”).

Source: SEC EDGAR

accession 0001641172-25-014296

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.